Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

European orphan drug designation awarded to AMY-101 for PNH

Sep. 1, 2014

FDA approves Promacta for severe aplastic anemia

Aug. 27, 2014

Phase III REGULATE-PCI of Revolixys Kit halted

Aug. 25, 2014

Apixaban granted FDA approval for DVT and PE

Aug. 22, 2014

Baxter's PEGylated rFVIII meets primary endpoint in phase III trial

Aug. 22, 2014

U.S. and Japanese group disclose new FIXa inhibitors

Aug. 20, 2014

Acetylon Pharmaceuticals patents novel HD3 inhibitors

Aug. 20, 2014

ALN-AT3 receives orphan drug designations in the E.U.

Aug. 8, 2014

Octapharma's Nuwiq receives E.U. approval for hemophilia A

Aug. 6, 2014

Chinese researchers divulge novel coagulation factor Xa inhibitors

Aug. 5, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 27, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 27, 2025
New drugs with the same old resistance tricks?
BioWorld
According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in 2020. And figures are rising, with...
OS Therapies heading to FDA with positive osteosarcoma data
BioWorld
With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies Inc. anticipates a regulatory filing...
Vilastobart set apart? Xilio phase II combo performs in CRC
BioWorld
“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...